Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.74 | N/A | -27.45% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.74 | N/A | -27.45% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions impacting performance. They did not provide specific guidance for future quarters.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.
Ligand Pharmaceuticals reported lower-than-expected earnings per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance. The stock's modest drop reflects market caution following the earnings report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WALMART INC
Feb 21, 2017